Mallinckrodt Inc

Mallinckrodt — Merger or Acquisition (March 2025)

15 slides from Mallinckrodt's merger presentation, Mar 13, 2025

  1. Slide 1: Creating a Global, Scaled, Diversified Pharmaceuticals Leader

    Creating a Global, Scaled, Diversified Pharmaceuticals Leader 1 March 13, 2025

  2. Slide 2: Disclosures: No Offer or Solicitation

    Disclosures No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which

  3. Slide 3: Disclosures: Forward-Looking Statements

    Disclosures There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties r

  4. Slide 4: Today's Speakers & Agenda

    Today’s Speakers & Agenda 4 Siggi Olafsson Mallinckrodt President & CEO Bryan Reasons Mallinckrodt CFO Mark Bradley Endo CFO Scott Hirsch Endo Interim CEO 1 Strategic Rationale Transaction Structure & Terms Combined Portfolio Potential Synergies Growth Opportunities 2 3 4 5

  5. Slide 5: Compelling Strategic Rationale

    Compelling Strategic Rationale Scaled and diversified branded pharmaceuticals portfolio Scaled generics business with a broad product portfolio Increased strategic and financial flexibility 5 Specialized and experienced team with strong compliance culture Meaningful synergy opportunities Strong bala

  6. Slide 6: Combination of Two Durable Portfolios

    Headquarters: Dublin, IRL Headquarters: Malvern, PA Annual 2024 • Net Revenue1 : $1.7bn • Adj. EBITDA1 : $464mm • Employees: ~2,700 • Net Revenue1 : $1.7bn • Adj. EBITDA1 : $637mm • Employees: ~3,000 Liquidity2 • Net Debt: $0.5bn • 2024 Net Leverage: 0.8x3 • Net Debt: $2.1bn • 2024 Net Leverage: 3.3

  7. Slide 7: Transaction Structure

    Transaction Structure 7 Combined Company Sterile Injectables and Generics Business Brands Business Step 1 Step 2 Creating 2 separate entities: 1 A leading, scaled brands business 2 A focused sterile injectables & generics business to be separated post-transaction

  8. Slide 8: Key Transaction Terms

    Key Transaction Terms Transaction Structure, Consideration & Ownership • Mallinckrodt will be the parent entity of the combined group and Mallinckrodt shareholders will own 50.1% and Endo shareholders will own 49.9% of the combined company • Endo shareholders to receive Mallinckrodt stock and $80mm

  9. Slide 9: Combined Company Creates a Scaled and Diversified Branded Portfolio

    Combined Company Creates a Scaled and Diversified Branded Portfolio… 9 Creates a pure play branded business Increased financial flexibility to drive strategic agenda Scaled platform that can be expanded through M&A Enhanced commercial position to pursue strategic opportunities Diversified pharma bus

  10. Slide 10: As Well as a Scaled Sterile Injectables and Generic Pharmaceuticals Business

    …As Well as a Scaled Sterile Injectables and Generic Pharmaceuticals Business 10 Broad product portfolio spanning multiple delivery technologies, formulations and dosage forms, as well as a leading controlled substances franchise Benefits from robust commercial capabilities, established manufacturin

  11. Slide 11: Heavily U.S. Focused Combined Footprint

    Heavily U.S. Focused Combined Footprint 11 Administrative Offices Manufacturing Regional Service Centers 5,700 Total Employees 17 Combined Manufacturing Facilities 30 Combined Distribution Centers Note: Figures as of March 12, 2025. 8 U.S. Manufacturing Facilities Branded Corp. and/or shared site Ge

  12. Slide 12: Enhanced Financial Flexibility Creates Avenue to Pursue Branded Growth Opportunities

    Develop additional capabilities across strategic therapeutic areas Enhanced Financial Flexibility Creates Avenue to Pursue Branded Growth Opportunities 12 Expand foundation to become a leader in areas of significant unmet need Grow branded platform through business development Drive long-term growth

  13. Slide 13: Compelling Rationale to Drive Future Growth

    Separation of sterile injectables and generics business would enable consistent return of capital to shareholders through stable, strong free cash flow Compelling Rationale to Drive Future Growth 13 Portfolio of well-established, diversified branded pharmaceuticals with room to grow Immediate scale,

  14. Slide 14: Appendix

    ©) Mallinckrodt 3 endo Pharmaceuticals Appendix

  15. Slide 15: Non-GAAP Definitions

    Non-GAAP Definitions Mallinckrodt Adjusted EBITDA Adjusted EBITDA represents net income or loss prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and adjusted for certain items that management believes are not reflective of the operational performance of the b

Mallinckrodt — Merger or Acquisition (March 2025) on 6ix